GHK-Cu's Mechanism Is Real. Its Human Trial Record Isn't There Yet.

In 1979, a biochemist named Loren Pickart and two colleagues ran a sample of human blood plasma through a chromatography column and pulled out a three-amino-acid chain wrapped around a single copper atom. They named it GHK, for the amino acids that build it: glycine, histidine, lysine.

The copper wasn’t an accident of the lab work. When the team purified the sample, copper and iron came out of the plasma still stuck to the tripeptide. Stripping the metals off with a chelating resin increased how much peptide they could recover by roughly eight-fold, which is how they confirmed the metal was riding along with GHK, not contaminating the batch. The sequence grips copper the way a claw grips a ball, tightly and by design, and it’s this copper-loaded form, GHK-Cu, that does nearly all the work the molecule is known for. This isn’t a synthetic invention grafted onto human biology. It was already there, in donated blood, identified decades ago as a copper-binding tripeptide native to human plasma, long before anyone tried to sell it in a jar.

What does GHK-Cu actually do in cells and animal wound models?

In the decades since, the mechanistic story got detailed, and it held up under repetition. One review paper lays the full mechanistic case out in detail. In cultured cells and animal wound models, the peptide-copper complex touches several pathways at once, not just one. It pushes up decorin, a protein that organizes collagen into the tight weave that holds a wound closed. It rebalances the enzymes that decide whether your body builds new tissue or clears out the old, nudging things toward repair. New blood vessels grow toward the injury site, what researchers call angiogenesis. Copper’s own chemistry adds antioxidant and anti-inflammatory effects on top of that, along with less scar-tissue buildup.

That’s an unusually complete list. Most peptides get credit for doing one of those things. GHK-Cu gets written up as doing five.

Here’s the detail that’s easy to miss reading the review papers stacked up on the topic. Almost all of that literature traces back to one lab: Pickart’s own. Decades of consistent findings from a single source is either the sign of a molecule that keeps working exactly as advertised, or the sign that nobody else has bothered to check.

How strong is the human evidence for GHK-Cu wound healing?

This is the part of the story that’s supposed to turn a mechanism into a treatment. It mostly doesn’t, not yet. The animal wound-healing data is real, and the biochemistry behind it (decorin, the MMP balance, new blood vessel growth) has replicated across separate experiments. But go looking for the equivalent trial in a person, someone with an actual wound and GHK-Cu given by injection to help it close, and you don’t find one.

Human clinical data on injectable, systemic GHK-Cu is thin next to everything published about the topical, cosmetic form. Nobody has run the trial that would connect a rat’s healed incision to a person’s. That’s the whole translational question, sitting unanswered.

The antioxidant question: mechanism versus measured effect

Copper doesn’t sit still inside a cell. Copper’s chemistry is what gives GHK-Cu its antioxidant reputation in the preclinical data, but that same chemistry can run in reverse. Instead of neutralizing the unstable oxygen molecules that damage cells, copper can help produce more of them. Whether it helps or harms comes down to dose and context, details nobody has pinned down for GHK-Cu at the amounts a real body would actually encounter.

Does it net out protective in an actual person? Nobody knows yet. The same mechanism that makes copper useful is the mechanism that could make it harmful, and no study has drawn that line either way for this peptide.

Does GHK-Cu work differently as a cream versus an injection?

GHK-Cu shows up in two very different places: skincare shelves and peptide-research literature. Only one of those has a randomized human trial behind it, and it isn’t the one most people would guess.

The one published randomized controlled trial of topical GHK-Cu skincare came back indistinguishable from placebo on the objective measurements the researchers tracked. Not a close result. Not a trend in the right direction. No measurable signal next to a placebo cream.

There’s a reasonable explanation, and it isn’t that the underlying biology is fake. A cream sitting on skin still has to cross the skin barrier to reach anything, and the data on how much actually gets through, at a level that would matter, doesn’t confirm it does. Push GHK into a vein instead, and it disappears fast, rat studies show it breaks down almost immediately in the bloodstream. Whether a smaller, localized dose placed under the skin sidesteps that speed of breakdown in a human body is untested.

What a real answer would require

A trial that actually settles this needs a delivery route matched to the claim being tested. A topical trial answers the skincare question and says nothing about GHK-Cu given systemically for wound or tissue repair. It needs concentration data confirming the compound actually arrives where it needs to work, not just a dose and a hope. And it needs an outcome measured the way the null topical trial measured its outcome: objectively, not by how a participant says their skin feels.

The field doesn’t lack ideas about GHK-Cu. It lacks the trial connecting the gene-expression story to a number a person, not a rat or a petri dish, actually produced.

Where the evidence actually lands

Three things are true about GHK-Cu at once. The molecule is native to the human body, not something foreign injected in from outside. In lab dishes and animal wounds, GHK-Cu touches nearly every part of the repair process, about as thorough a preclinical case as any molecule gets. And the only human trial anyone has actually run, the topical skincare RCT, showed nothing measurable next to placebo.

None of those facts cancels the others. A strong cell-biology story paired with a null human trial in one delivery route doesn’t mean the mechanism is fake. It also doesn’t mean the topical products on shelves are doing what their labels imply. It means the injectable, systemic case, the one closest to the promising animal data, hasn’t been tested in a person yet. If you’re considering GHK-Cu for something beyond skincare, that’s the gap worth knowing about before you decide.